Amgen agrees to develop biosimilars for Chinese market
Increasing its global footprint in the biosimilars market, Amgen announced Sept. 26 that it had formed an exclusive co-development agreement with Chinese drug manufacturer Simcere Pharmaceutical Group. The agreement aims to bring four oncology and inflammation biosimilars in Amgen’s portfolio to commercialization in China. The Thousand Oaks-based biotechnology company will produce and submit approval applications Read More →
Read More →Amgen reaffirms earnings outlook after hurricane hits Puerto Rico
After reviewing the impacts to its Puerto Rico manufacturing facility from Hurricane Maria, Thousand Oaks biotech giant Amgen reaffirmed its earnings outlook Sept. 25 and said that outreach to impacted staff was ongoing. The storm did not damage any product or in-process inventory at the plant, and the company said it did not expect any Read More →
Read More →FDA approves Amgen cancer treatment biosimilar Mvasi
The U.S. Food and Drug Administration approved a cancer treatment biosimilar developed in partnership between Allergan and Thousand Oaks-based Amgen, the company announced Sept. 13. Mvasi was approved to treat five types of cancer in combination with other therapies. “The approval of Mvasi marks a significant milestone for healthcare practitioners and patients as the first Read More →
Read More →
Our view: Congress should allow ‘dreamers’ to stay in U.S.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Study finds Amgen asthma drug is effective
An asthma drug being developed by Thousand Oaks-based Amgen and AstraZeneca showed significant yearly reduction for patients, according to a study published in the New England Journal of Medicine Sept. 6. Patients with severe, uncontrolled asthma using tezepelumab saw a drop in annual exacerbation compared with patients taking a placebo, Amgen said in a news Read More →
Read More →Our view: Sexual abuse bill would protect entrepreneurs from investors
Sen. Hannah-Beth Jackson (D-Santa Barbara) has been getting well-deserved national attention for a timely effort to address sexual abuse in the venture capital industry. She has introduced a draft of SB 224, a bill that aims to deter investors from making unwanted sexual advances to entrepreneurs seeking funding. Her effort comes at a time when Read More →
Read More →Amgen partnering with Humana to study diseases
Thousand Oaks biotechnology giant Amgen announced a collaboration agreement with Louisville, Ky.-based Humana on Aug. 17 to study conditions like cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer. The two companies currently have six projects underway focusing on improving health care quality and costs with data from Humana’s 13 million members, including wearable technology, Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
